Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
44.74
-1.28 (-2.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
908,357
Open
46.14
Bid (Size)
41.21 (5)
Ask (Size)
47.37 (1)
Prev. Close
46.02
Today's Range
44.57 - 47.39
52wk Range
38.60 - 77.32
Shares Outstanding
308,456,852
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
July 02, 2024
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of...
Via
Benzinga
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
July 02, 2024
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Performance
YTD
-24.30%
-24.30%
1 Month
+11.77%
+11.77%
3 Month
-20.72%
-20.72%
6 Month
-24.30%
-24.30%
1 Year
-35.03%
-35.03%
More News
Read More
Assessing Legend Biotech: Insights From 15 Financial Analysts
June 21, 2024
Via
Benzinga
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
June 17, 2024
Via
Benzinga
Unveiling 18 Analyst Insights On Legend Biotech
June 04, 2024
Via
Benzinga
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
May 14, 2024
Via
Benzinga
Analyst Ratings For Legend Biotech
April 17, 2024
Via
Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
June 09, 2024
Via
Benzinga
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
June 03, 2024
From
Legend Biotech
Via
Business Wire
Unveiling 9 Analyst Insights On Legend Biotech
April 01, 2024
Via
Benzinga
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
May 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
May 13, 2024
Via
Talk Markets
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
May 13, 2024
Via
InvestorPlace
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
May 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
April 22, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Via
Benzinga
Exposures
Product Safety
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
April 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
April 08, 2024
Via
Benzinga
Exposures
Product Safety
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
April 05, 2024
From
Legend Biotech Corporation
Via
Business Wire
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
March 20, 2024
Via
Benzinga
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
March 19, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
March 18, 2024
Via
Benzinga
Exposures
Product Safety
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
March 15, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
March 13, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.